AMEERA-3 is an open-label randomized phase II study of amcenestrant (SAR439859) versus treatment of physician’s choice (fulvestrant/aromatase inhibitors/estrogen receptor modular) in locally advanced or metastatic ER + breast cancer. The gene discussed is CYP19A1; the disease is breast cancer.